Organon & Co.(OGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,594 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
OGN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Organon & Co. (OGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OGN at 50.5/100 on a 32-signal composite quality model, placing it at rank #1,594 of 2,961 stocks — the bottom half of the AI-ranked universe. OGN scores in the top quartile across earnings quality (91.9), institutional flow (91.4), revenue scale (80.6). Areas of concern include revenue growth (19.4) and profitability (31.5), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Organon & Co. reports quarterly revenue of $1.6B, net income of $108.0M, an operating margin of 11.8%. Top institutional holders of OGN by reported 13-F value include BlackRock, Pentwater Capital Management, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. OGN trades on the NYSE exchange and files with the SEC under CIK 1821825. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organon & Co. directly from SEC EDGAR. Organon & Co.'s 13F Pro composite quality score has ranged between 48 and 65 since 2022, currently 50.5 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.6B
Net Income
Q2 2026
$108.0M
Free Cash Flow
Q2 2026
$65.0M
Operating Margin
Q2 2026
11.8%
ROIC
Q2 2026
7.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-2.9% YoYNet Income
-78.4% YoYEPS (Diluted)
-78.4% YoYTotal Assets
-1.8% YoYTotal Debt
-2.9% YoYOp. Cash Flow
-25.5% YoYFree Cash Flow
-29.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.22B -2.9% | $6.40B +2.2% | $6.26B +1.4% | $6.17B -2.1% | $6.30B -3.5% | $6.53B |
| Net Income | $187.0M -78.4% | $864.0M -15.5% | $1.02B +11.6% | $917.0M -32.1% | $1.35B -37.5% | $2.16B |
| EPS (Diluted) | $0.72 -78.4% | $3.33 -16.5% | $3.99 +11.1% | $3.59 -32.4% | $5.31 -37.7% | $8.52 |
| Total Assets | $12.87B -1.8% | $13.10B +8.6% | $12.06B +10.1% | $10.96B +2.6% | $10.68B +5.7% | $10.11B |
| Total Debt | $8.66B -2.9% | $8.92B +1.7% | $8.77B -1.7% | $8.92B -2.4% | $9.14B | $0.00 |
| Operating Cash Flow | $700.0M -25.5% | $939.0M +17.5% | $799.0M -6.9% | $858.0M | — | — |
| Free Cash Flow | $538.0M -29.6% | $764.0M +39.4% | $548.0M -17.2% | $662.0M | — | — |
Get alerted when OGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Organon & Co. including:
Top Institutional Holders of OGN
BlackRock, Inc.
$434.0M32,056,866 shPentwater Capital Management LP
$245.1M18,100,000 shVANGUARD PORTFOLIO MANAGEMENT LLC
$204.9M15,132,118 shVANGUARD CAPITAL MANAGEMENT LLC
$161.3M11,909,865 shSTATE STREET CORP
$130.8M9,659,371 shGOLDMAN SACHS GROUP INC
$70.4M5,199,002 shUBS Group AG
$65.8M4,856,529 shGEODE CAPITAL MANAGEMENT, LLC
$65.2M4,815,610 shMan Group plc
$56.6M4,180,500 shAQR Arbitrage LLC
$52.4M3,880,354 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $434.0M | 32,056,866 |
| Pentwater Capital Management LP | $245.1M | 18,100,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $204.9M | 15,132,118 |
| VANGUARD CAPITAL MANAGEMENT LLC | $161.3M | 11,909,865 |
| STATE STREET CORP | $130.8M | 9,659,371 |
| GOLDMAN SACHS GROUP INC | $70.4M | 5,199,002 |
| UBS Group AG | $65.8M | 4,856,529 |
| GEODE CAPITAL MANAGEMENT, LLC | $65.2M | 4,815,610 |
| Man Group plc | $56.6M | 4,180,500 |
| AQR Arbitrage LLC | $52.4M | 3,880,354 |
Companies Similar to OGN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Viatris Inc
BECTON DICKINSON & CO
Merck & Co., Inc.
GE HealthCare Technologies Inc.
AVANOS MEDICAL, INC.
ZIMMER BIOMET HOLDINGS, INC.
PFIZER INC
Chemours Co
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put OGN on your watchlist
Track score changes the day Organon & Co. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OGN a good stock to buy?
13F Pro's AI-powered analysis of Organon & Co. (OGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OGN are available on the OGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OGN is classified as a mid company.
Which hedge funds own OGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Organon & Co.'s investment landscape.